Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.
2.

ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.

Bachmann CJ, Philipsen A, Hoffmann F.

Dtsch Arztebl Int. 2017 Mar 3;114(9):141-148. doi: 10.3238/arztebl.2017.0141.

3.

Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.

Wietecha LA, Clemow DB, Buchanan AS, Young JL, Sarkis EH, Findling RL.

CNS Neurosci Ther. 2016 Jul;22(7):546-57. doi: 10.1111/cns.12533. Epub 2016 Feb 28.

4.

Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.

Zhang C, Kutyifa V, Moss AJ, McNitt S, Zareba W, Kaufman ES.

J Cardiovasc Electrophysiol. 2015 Oct;26(10):1039-44. doi: 10.1111/jce.12739. Epub 2015 Aug 6.

5.

Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants.

Weyandt LL, Oster DR, Marraccini ME, Gudmundsdottir BG, Munro BA, Zavras BM, Kuhar B.

Psychol Res Behav Manag. 2014 Sep 9;7:223-49. doi: 10.2147/PRBM.S47013. eCollection 2014. Review.

6.

A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

Maneeton N, Maneeton B, Intaprasert S, Woottiluk P.

Neuropsychiatr Dis Treat. 2014 Aug 1;10:1439-49. doi: 10.2147/NDT.S62714. eCollection 2014.

7.

Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.

Huss M, Ginsberg Y, Arngrim T, Philipsen A, Carter K, Chen CW, Gandhi P, Kumar V.

Clin Drug Investig. 2014 Sep;34(9):639-49.

8.

The weighed core symptom scale and prediction of ADHD in adults - objective measures of remission and response to treatment with methylphenidate.

Edebol H, Helldin L, Norlander T.

Clin Pract Epidemiol Ment Health. 2013 Oct 18;9:171-9. doi: 10.2174/1745017901309010171. eCollection 2013.

9.

The safety and efficacy of methylphenidate and dexmethylphenidate in adults with attention deficit/hyperactivity disorder.

Sopko MA Jr, Caberwal H, Chavez B.

J Cent Nerv Syst Dis. 2010 Aug 3;2:15-30. Print 2010.

10.

Impulsivity is associated with uric acid: evidence from humans and mice.

Sutin AR, Cutler RG, Camandola S, Uda M, Feldman NH, Cucca F, Zonderman AB, Mattson MP, Ferrucci L, Schlessinger D, Terracciano A.

Biol Psychiatry. 2014 Jan 1;75(1):31-7. doi: 10.1016/j.biopsych.2013.02.024. Epub 2013 Apr 10.

11.

Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

Mattingly GW, Weisler RH, Young J, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner B, Goodman DW.

BMC Psychiatry. 2013 Jan 29;13:39. doi: 10.1186/1471-244X-13-39.

12.

Rates of undiagnosed attention deficit hyperactivity disorder in London drug and alcohol detoxification units.

Huntley Z, Maltezos S, Williams C, Morinan A, Hammon A, Ball D, Marshall EJ, Keaney F, Young S, Bolton P, Glaser K, Howe-Forbes R, Kuntsi J, Xenitidis K, Murphy D, Asherson PJ.

BMC Psychiatry. 2012 Dec 6;12:223. doi: 10.1186/1471-244X-12-223.

13.

Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults.

Mick E, McManus DD, Goldberg RJ.

Eur Neuropsychopharmacol. 2013 Jun;23(6):534-41. doi: 10.1016/j.euroneuro.2012.06.011. Epub 2012 Jul 15. Review.

14.

Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate.

Ginsberg Y, Hirvikoski T, Grann M, Lindefors N.

Eur Arch Psychiatry Clin Neurosci. 2012 Dec;262(8):705-24. doi: 10.1007/s00406-012-0317-8. Epub 2012 Apr 21.

15.

An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults.

Wilens TE, Morrison NR, Prince J.

Expert Rev Neurother. 2011 Oct;11(10):1443-65. doi: 10.1586/ern.11.137. Review.

16.

Achievement and maintenance of the new impact factor 2010.

Falkai P, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2011 Sep;261(6):387-9. doi: 10.1007/s00406-011-0237-z. No abstract available.

18.

Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.

Retz W, Rösler M, Ose C, Scherag A, Alm B, Philipsen A, Fischer R, Ammer R; Study Group.

World J Biol Psychiatry. 2012 Jan;13(1):48-59. doi: 10.3109/15622975.2010.540257. Epub 2010 Dec 14.

19.

European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P.

BMC Psychiatry. 2010 Sep 3;10:67. doi: 10.1186/1471-244X-10-67. Review.

20.

Supplemental Content

Support Center